-
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
-
ChemBase ID:
6075
-
Molecular Formular:
C24H29N7O
-
Molecular Mass:
431.53336
-
Monoisotopic Mass:
431.24335858
-
SMILES and InChIs
SMILES:
c1(N[C@@H](CO)CC)nc(c2c(n(cn2)C(C)C)n1)NCc1ccc(cc1)c1ncccc1
Canonical SMILES:
CC[C@@H](Nc1nc(NCc2ccc(cc2)c2ccccn2)c2c(n1)n(cn2)C(C)C)CO
InChI:
InChI=1S/C24H29N7O/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30)/t19-/m1/s1
InChIKey:
HOCBJBNQIQQQGT-LJQANCHMSA-N
-
Cite this record
CBID:6075 http://www.chembase.cn/molecule-6075.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
|
|
|
|
|
IUPAC Traditional name
|
|
(2R)-2-{[9-isopropyl-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)purin-2-yl]amino}butan-1-ol
|
|
|
|
|
Synonyms
|
|
(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
|
|
(2R)-2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-butanol-1
|
|
(R)-2-(1-Hydroxybut-2-ylamino)-6-[4-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine
|
|
C&R8
|
|
CR8
|
|
|
|
|
CAS Number
|
|
|
MDL Number
|
|
|
PubChem SID
|
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
|
Acid pKa
|
14.336885
|
H Acceptors
|
7
|
H Donor
|
3
|
LogD (pH = 5.5)
|
3.648268
|
LogD (pH = 7.4)
|
3.7074037
|
Log P
|
3.7081864
|
Molar Refractivity
|
128.7516 cm3
|
Polarizability
|
49.398693 Å3
|
Polar Surface Area
|
100.78 Å2
|
Rotatable Bonds
|
9
|
Lipinski's Rule of Five
|
true
|
|
Log P
|
4.24
|
LOG S
|
-4.39
|
Solubility (Water)
|
1.77e-02 g/l
|
DETAILS
DETAILS
DrugBank
Sigma Aldrich
Sigma Aldrich -
C3249
|
Biochem/physiol Actions CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). CR8 is a more potent pyridyl analogue of roscovitine (Cat. No. R7772). In comparison to roscovirtine, the compound gains in potency toward CK1, which is involved in amyloid-β formation. The R-CR8 enantiomer is slightly more potent than S. CR8 is around 30 times more potent at cellular assay then roscovitine. |
PATENTS
PATENTS
PubChem Patent
Google Patent